<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768989</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-376</org_study_id>
    <nct_id>NCT00768989</nct_id>
  </id_info>
  <brief_title>Phase IIB Pilot of Atazanavir + Raltegravir</brief_title>
  <acronym>SPARTAN</acronym>
  <official_title>A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination With Tenofovir/Emtricitabine QD in Treatment Naive HIV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of atazanavir and raltegravir
      taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to
    support further clinical development in this population.
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Level &lt;50 Copies/mL at Week 24</measure>
    <time_frame>At Week 24 from Baseline</time_frame>
    <description>The number of HIV 1-infected treatment-naive participants with an HIV RNA level &lt;50 copies/mL after 24 weeks of treatment. Confirmed virologic response noncompleter=failure (NC=F); noncompleter=missing (NC=M); virologic response-observed cases (VR-OC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Nonresponders at Week 8</measure>
    <time_frame>At Week 8 from Baseline</time_frame>
    <description>Participants were classified as nonresponders if they had an HIV RNA level ≥400 copies/mL and a decrease from baseline &lt;2 log10 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels &lt;50 Copies/mL at Weeks 48 and 96</measure>
    <time_frame>At Weeks 48 and 96 from Baseline</time_frame>
    <description>Participant HIV RNA level was determined at Weeks 48 and 96 using the Roche Amplicor® Ultrasensitive Assay Version 1. VR-OC=Virologic response-observed cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 24</measure>
    <time_frame>At Week 24 from Baseline</time_frame>
    <description>NC=F: noncompleter=failure; NC=M: noncompleter=missing; VR-OC: virologic response-observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 48</measure>
    <time_frame>At Week 48 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 96</measure>
    <time_frame>At Week 96 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Absolute Cluster of Differentiation 4 Cell Count</measure>
    <time_frame>From Baseline to Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Death as Outcome, AEs Leading to Discontinuation, SAEs Leading to Discontinuation</measure>
    <time_frame>Week 1 to Week 96, continuously</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in drug dependency or drug abuse, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Mean Change From Baseline in Total Cholesterol Levels</measure>
    <time_frame>From Baseline to Week 24 and Week 48</time_frame>
    <description>The mean change from baseline in participant fasting lipids was determined using fasting serum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Bilirubin Level</measure>
    <time_frame>From Baseline to Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Electrocardiogram Findings</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>The incidence of QRS wave widening and QT and PR prolongation on participant electrocardiogram findings were evaluated at study Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Maximum Observed Plasma Concentration (Cmax) in 1 Dosing Interval</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Cmax in 1 Dosing Interval</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Time of Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Tmax</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Trough Plasma Concentration (Cmin) 12 Hours Postdose</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Cmin 12 Hours Postdose</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Cmin Prior to the Morning Dose</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Cmin Prior to the Morning Dose</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Area Under the Concentration Curve From Time 0 to 12 Hours (AUC [0-12h]) in 1 Dosing Interval</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir AUC (0-12h) in 1 Dosing Interval</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Area Under the Concentration Curve From Time 0 to 24 Hours (AUC [0-24h]) in 1 Dosing Interval</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>AUC (0-24h) was estimated by multiplying AUC (0-12h) by 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Individual Inhibitory Quotient (IQ)</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
    <description>Individual IQ was defined at Cmin at Week 2 divided by the protein binding adjusted EC90 (ie, the drug concentration observed to inhibit virion production by 90% in a cell-based assay) values for Atazanavir that were derived from individual participant clinical isolates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atazanavir Terminal Elimination Half Life</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raltegravir Terminal Elimination Half Life</measure>
    <time_frame>At Week 2 from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Laboratory Test Results With Worst Toxicity of Grades 1 to 4 Among All Treated Participants</measure>
    <time_frame>While on treatment from Baseline through Week 96</time_frame>
    <description>ULN=upper limit of normal. Hematocrit(%) Grade (Gr) 1: ≥28.5-&lt;31; Gr 2: ≥24-&lt;28.5; Gr 3: ≥19.5-&lt;24; Gr 4: &lt;19.5. Hemoglobin (g/dL) Gr 1: 9.5-11; Gr 2: 8-9.4; Gr 3: 6.5-7.9; Gr 4: &lt;6.5. Platelets (/mm^3) Gr 1: 75,000-99,000; Gr 2: 50,000-74,999; Gr 3: 20,000-49,999; Gr 4: &lt;20,000. White Blood Cells (/mm^3) Gr 1: &gt;2500-4000; Gr 2: &gt;1000-&lt;2500; Gr 3: &gt;800-&lt;1000; Gr 4: &lt;800. . Prothrombin time (seconds) Gr 1: 1.01-1.25*ULN; Gr 2: 1.26-1.5*ULN; Gr 3: 1.51-3*ULN; Gr 4: &gt;3*ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4</measure>
    <time_frame>While on treatment from Baseline through Week 96</time_frame>
    <description>Blood urea nitrogen Gr 1:1.25-2.5*ULN;Gr 2:2.6-5.0*ULN; Gr 3:5.1-10*ULN; Gr 4:&gt;10*ULN. Creatinine (mg/dL) Gr 1: 1.1-1.5 *ULN; Gr 2: 1.6-3*ULN: Gr 3: 3.1-6*ULN; Gr 4: &gt;6*ULN. Hypercarbia (meq/L)Gr 1: 33-36; Gr 2:37-40; Gr 3: 41-45; Gr 4:&gt;45. Hypocarbia (meq/L)Gr 1:19-21; Gr 2: 15-18; Gr 3: 10-14; Gr 4:&lt;10. Hypercalcemia (mg/dL)Gr 1:10.6-11.5;Gr 2:11.6-12.5; Gr 3:12.6-13.5;Gr 4: &gt;13.5. Hypocalcemia (mg/dL)Gr 1: 8.4-7.8;Gr 2:7.7-7; Gr 3:6.9-6.1; Gr 4: &lt;6.1.Hyperchloremia(meq/L)Gr 1:113-116; Gr 2:117-120; Gr 3:121-125; Gr 4: &gt;125.Hypochloremia(meq/L)Gr 1: 90-93; Gr 2: 85-89; Gr 3:80-84; Gr 4:&lt;80.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4 (Continued)</measure>
    <time_frame>While on treatment from Baseline through Week 96</time_frame>
    <description>Hyperkalemia(meq/L) Gr 1: 5.6-6; Gr 2: 6.1-6.5; Gr 3: 6.6-7; Gr4: &gt;7. Hypokalemia(meq/L) Gr 1: 3-3.4; Gr 2: 2.5-2.9; Gr 3: 2-2.4; Gr 4:&lt;2. Hypernatremia (meq/L) Gr 1: 148-150; Gr 2: 151-157; Gr 3: 148-165; Gr 4: &gt;165. Hyponatremia (meq/L) Gr 1: 130-132; Gr 2: 123-129; Gr 3: 116-122; Gr 4: &gt;115.Hyperglycemia(mg/dL)Gr 1: 116-160; Gr 2: 161-250; Gr 3: 251-500; Gr 4: &gt;500. Hypoglycemia(mg/dL)Gr 1: 55-64; Gr 2: 40-54; Gr 3:30-39;Gr 4:&lt;30.Creatine kinase (IU/L) Gr 1: &gt;ULN-1.5*ULN; Gr 2: 1.5-3*ULN; Gr 3: &gt;3-6*ULN; Gr 4: &gt;6.0*ULN. Albumin (g/dL) Gr 1: &lt;LLN-30; Gr 2: &lt;30-20; Gr 3&amp;4: &lt;20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Enzyme and Urine Laboratory Test Results With Worst Toxicity of Grades 1 to 4</measure>
    <time_frame>While on treatment from Baseline through Week 96</time_frame>
    <description>AST/SGOT=Aspartate aminotransferase/serum glutamate oxaloacetate transaminase; ALT/SGPT=Alanine transaminase/serum glutamic pyruvic transaminase. Bilirubin (mg/dL)Gr 1: 1.1-1.5*ULN;Gr 2:1.6-2.5*ULN;Gr3:2.6-5*ULN;Gr4:&gt;5*ULN.AST/SGOT(U/L)Gr 1:1.25-2.5*ULN;Gr 2: 2.6-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.ALT/SGPT (U/L)Gr 1:1.25-2.5*ULN;Gr 2:1.4-2.09*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN. Lipase(U/L)Gr 1:1.1-1.39*ULN;Gr 2:&gt;1.5-2*ULN;Gr 3:2.5-5;Gr 4:5*ULN.Proteinuria(g/24 hr loss)Gr 1:1+or &lt;1;Gr 2:2-3+or&gt;1-2; Gr 3:4+or&gt;2-3.5;Gr4:&gt;3.5.Creatine kinase(IU/L)Gr1:2-3*ULN;Gr 2:3.1-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Atazanavir + Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir + Ritonavir + Tenofovir /Emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsules, Oral, 300 mg, twice daily, 96 weeks</description>
    <arm_group_label>Atazanavir + Raltegravir</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>BMS-232632</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Tablet, Oral, 400 mg, twice daily, 96 weeks</description>
    <arm_group_label>Atazanavir + Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsules, Oral, 300 mg, once daily, 96 weeks</description>
    <arm_group_label>Atazanavir + Ritonavir + Tenofovir /Emtricitabine</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>BMS-232632</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Capsules, Oral, 100 mg, once daily, 96 weeks</description>
    <arm_group_label>Atazanavir + Ritonavir + Tenofovir /Emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/Emtricitabine</intervention_name>
    <description>Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks</description>
    <arm_group_label>Atazanavir + Ritonavir + Tenofovir /Emtricitabine</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human Immunodeficiency Virus (HIV)-1 positive status

          -  HIV ribonucleic acid (RNA) level &gt;=5000 copies/mL

          -  Antiretroviral treatment-naive

          -  Absolute Cluster of Differentiation 4 (CD4) cell count meeting 1 of the following
             criteria:

          -  &lt;350 cells/mm^3

          -  Screening CD4 &gt;=350 and &lt;=500 cells/mm^3 ONLY if at least 1 of the following
             conditions apply:

               -  Screening HIV RNA level &gt;100,000 copies/mL, or

               -  CD4 decline &gt;50-100 cells/mm^3/year, or

               -  Age &gt;=55 years

          -  Any CD4 cell count, if participant has a history of an acquired immune deficiency
             syndrome-defining illness

          -  Medically stable

        Exclusion Criteria:

          -  Screening HIV genotype showing resistance to any component of the study regimen
             (Atazanavir, Raltegravir, Tenofovir/Emtricitabine)

          -  Hepatitis B or hepatitis C coinfection

          -  History of or current cardiac disease

          -  Electrocardiogram findings:

          -  PR Interval &gt;260 msec (severe 1st degree atrioventricular block)

          -  QRS Interval &gt;120 msec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Center For HIV/AIDS</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physicians Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aaron Diamond AIDS Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Ft Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diversified Medical Practices, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires, Bs As</city>
        <state>Buenos Aires</state>
        <zip>1141</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1264</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600CTO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <results_first_submitted>October 19, 2011</results_first_submitted>
  <results_first_submitted_qc>December 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2012</results_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from sites in Argentina (n=21 randomized), France (n=26 randomized), and the United States (n=47 randomized).</recruitment_details>
      <pre_assignment_details>Of 167 participants enrolled, 94 were randomized to treatment; 1 withdrew consent after randomization but prior to study dosing. Of the 73 not randomized, 5 withdrew consent, 1 lost to follow up; 1 poor/noncompliance; 61 no longer met study criteria, and 5 for other reasons. The trial was terminated early.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atazanavir + Raltegravir</title>
          <description>Atazanavir 300 mg twice daily plus Raltegravir 400 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
          <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Prior to Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 24 to Prior to Week 36</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>On or After Week 36</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not attend termination visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Termination</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atazanavir + Raltegravir</title>
          <description>Atazanavir 300 mg twice daily plus Raltegravir 400 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
          <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="10.90"/>
                    <measurement group_id="B2" value="41.6" spread="10.87"/>
                    <measurement group_id="B3" value="40.2" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA Level at Baseline</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="0.57"/>
                    <measurement group_id="B2" value="4.9" spread="0.66"/>
                    <measurement group_id="B3" value="4.9" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA Distribution at Baseline</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 30,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30,000 to &lt;100,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100,000 to &lt;500,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=500,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Cluster of Differentiation 4 (CD4) Cell Count at Baseline</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256.2" spread="116.79"/>
                    <measurement group_id="B2" value="261.2" spread="134.93"/>
                    <measurement group_id="B3" value="257.8" spread="122.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Distribution at Baseline</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to &lt; 100 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 to &lt; 200 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>200 to &lt; 350 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>350 to &lt; 500 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 500 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Level &lt;50 Copies/mL at Week 24</title>
        <description>The number of HIV 1-infected treatment-naive participants with an HIV RNA level &lt;50 copies/mL after 24 weeks of treatment. Confirmed virologic response noncompleter=failure (NC=F); noncompleter=missing (NC=M); virologic response-observed cases (VR-OC).</description>
        <time_frame>At Week 24 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Level &lt;50 Copies/mL at Week 24</title>
          <description>The number of HIV 1-infected treatment-naive participants with an HIV RNA level &lt;50 copies/mL after 24 weeks of treatment. Confirmed virologic response noncompleter=failure (NC=F); noncompleter=missing (NC=M); virologic response-observed cases (VR-OC).</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NC=F (n=63, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC=M (n=58, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VR-OC (n=52, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Nonresponders at Week 8</title>
        <description>Participants were classified as nonresponders if they had an HIV RNA level ≥400 copies/mL and a decrease from baseline &lt;2 log10 copies/mL.</description>
        <time_frame>At Week 8 from Baseline</time_frame>
        <population>The first 60 participants randomized, who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nonresponders at Week 8</title>
          <description>Participants were classified as nonresponders if they had an HIV RNA level ≥400 copies/mL and a decrease from baseline &lt;2 log10 copies/mL.</description>
          <population>The first 60 participants randomized, who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels &lt;50 Copies/mL at Weeks 48 and 96</title>
        <description>Participant HIV RNA level was determined at Weeks 48 and 96 using the Roche Amplicor® Ultrasensitive Assay Version 1. VR-OC=Virologic response-observed cases.</description>
        <time_frame>At Weeks 48 and 96 from Baseline</time_frame>
        <population>The study terminated early, and this analysis was done only at Week 48 using VR-OC for participants who reached Week 48 when the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels &lt;50 Copies/mL at Weeks 48 and 96</title>
          <description>Participant HIV RNA level was determined at Weeks 48 and 96 using the Roche Amplicor® Ultrasensitive Assay Version 1. VR-OC=Virologic response-observed cases.</description>
          <population>The study terminated early, and this analysis was done only at Week 48 using VR-OC for participants who reached Week 48 when the study was terminated.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 24</title>
        <description>NC=F: noncompleter=failure; NC=M: noncompleter=missing; VR-OC: virologic response-observed</description>
        <time_frame>At Week 24 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 24</title>
          <description>NC=F: noncompleter=failure; NC=M: noncompleter=missing; VR-OC: virologic response-observed</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NC=F (n= 63, 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC=M (n=58, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VR-OC (n=52, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 48</title>
        <time_frame>At Week 48 from Baseline</time_frame>
        <population>The study terminated early, and this analysis was only done at Week 48 using VR-OC for participants who reached Week 48 when the study was terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 48</title>
          <population>The study terminated early, and this analysis was only done at Week 48 using VR-OC for participants who reached Week 48 when the study was terminated.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 96</title>
        <time_frame>At Week 96 from Baseline</time_frame>
        <population>This analysis was not preformed due to early termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels &lt;400 Copies/mL at Week 96</title>
          <population>This analysis was not preformed due to early termination of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Absolute Cluster of Differentiation 4 Cell Count</title>
        <time_frame>From Baseline to Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and had baseline and timepoint results.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Absolute Cluster of Differentiation 4 Cell Count</title>
          <population>All randomized participants who received at least 1 dose of study medication and had baseline and timepoint results.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean change from Baseline at Week 2 (n=59, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="11.886"/>
                    <measurement group_id="O2" value="63.1" spread="14.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 4 (n=62, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="12.238"/>
                    <measurement group_id="O2" value="100.1" spread="19.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 8 (n=60, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.5" spread="12.297"/>
                    <measurement group_id="O2" value="111.9" spread="16.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 12 (n=62, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.6" spread="13.964"/>
                    <measurement group_id="O2" value="129.3" spread="20.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 16 (n=58, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.6" spread="12.789"/>
                    <measurement group_id="O2" value="127.6" spread="19.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 20 (n=58, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.5" spread="12.189"/>
                    <measurement group_id="O2" value="140.7" spread="19.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 24 (n=55, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.0" spread="16.954"/>
                    <measurement group_id="O2" value="127.0" spread="17.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Death as Outcome, AEs Leading to Discontinuation, SAEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in drug dependency or drug abuse, or is an important medical event.</description>
        <time_frame>Week 1 to Week 96, continuously</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Death as Outcome, AEs Leading to Discontinuation, SAEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in drug dependency or drug abuse, or is an important medical event.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Mean Change From Baseline in Total Cholesterol Levels</title>
        <description>The mean change from baseline in participant fasting lipids was determined using fasting serum samples.</description>
        <time_frame>From Baseline to Week 24 and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication. N=number of participants analyzed; n=number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir 300 mg twice daily plus Raltegravir 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Mean Change From Baseline in Total Cholesterol Levels</title>
          <description>The mean change from baseline in participant fasting lipids was determined using fasting serum samples.</description>
          <population>All randomized participants who received at least 1 dose of study medication. N=number of participants analyzed; n=number of participants with measurements for that time point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=56, 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.6" spread="3.833"/>
                    <measurement group_id="O2" value="169.6" spread="6.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 24 (n=51, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="4.367"/>
                    <measurement group_id="O2" value="15.1" spread="6.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 48 (n=38, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="3.040"/>
                    <measurement group_id="O2" value="17.1" spread="4.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Bilirubin Level</title>
        <time_frame>From Baseline to Week 24 and Week 48</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Bilirubin Level</title>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean change from Baseline at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.2032"/>
                    <measurement group_id="O2" value="1.71" spread="0.2234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change from Baseline at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="0.2176"/>
                    <measurement group_id="O2" value="1.52" spread="0.2206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Electrocardiogram Findings</title>
        <description>The incidence of QRS wave widening and QT and PR prolongation on participant electrocardiogram findings were evaluated at study Week 24.</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Electrocardiogram Findings</title>
          <description>The incidence of QRS wave widening and QT and PR prolongation on participant electrocardiogram findings were evaluated at study Week 24.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="1.019"/>
                    <measurement group_id="O2" value="3.6" spread="1.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc Friderica Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.001"/>
                    <measurement group_id="O2" value="6.0" spread="3.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="2.101"/>
                    <measurement group_id="O2" value="4.9" spread="2.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Maximum Observed Plasma Concentration (Cmax) in 1 Dosing Interval</title>
        <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Maximum Observed Plasma Concentration (Cmax) in 1 Dosing Interval</title>
          <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
          <population>All randomized participants who received at least 1 dose of study medication and were evaluable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3506.5" spread="1366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir Cmax in 1 Dosing Interval</title>
        <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Cmax in 1 Dosing Interval</title>
          <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
          <population>All randomized participants who received at least 1 dose of study medication and were evaluable.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1577.0" spread="2516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Time of Maximum Observed Plasma Concentration (Tmax)</title>
        <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Time of Maximum Observed Plasma Concentration (Tmax)</title>
          <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir Tmax</title>
        <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Tmax</title>
          <description>Serial blood samples were collected over a 12-hour period after the morning dose at Week 2.</description>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="0.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Trough Plasma Concentration (Cmin) 12 Hours Postdose</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Trough Plasma Concentration (Cmin) 12 Hours Postdose</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.1" spread="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir Cmin 12 Hours Postdose</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Cmin 12 Hours Postdose</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Cmin Prior to the Morning Dose</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Cmin Prior to the Morning Dose</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng*h / mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879.25" spread="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir Cmin Prior to the Morning Dose</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Cmin Prior to the Morning Dose</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.42" spread="577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Area Under the Concentration Curve From Time 0 to 12 Hours (AUC [0-12h]) in 1 Dosing Interval</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Area Under the Concentration Curve From Time 0 to 12 Hours (AUC [0-12h]) in 1 Dosing Interval</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19903.4" spread="8088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir AUC (0-12h) in 1 Dosing Interval</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir AUC (0-12h) in 1 Dosing Interval</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6446.4" spread="6432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Area Under the Concentration Curve From Time 0 to 24 Hours (AUC [0-24h]) in 1 Dosing Interval</title>
        <description>AUC (0-24h) was estimated by multiplying AUC (0-12h) by 2.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Area Under the Concentration Curve From Time 0 to 24 Hours (AUC [0-24h]) in 1 Dosing Interval</title>
          <description>AUC (0-24h) was estimated by multiplying AUC (0-12h) by 2.</description>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39806.7" spread="16176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Individual Inhibitory Quotient (IQ)</title>
        <description>Individual IQ was defined at Cmin at Week 2 divided by the protein binding adjusted EC90 (ie, the drug concentration observed to inhibit virion production by 90% in a cell-based assay) values for Atazanavir that were derived from individual participant clinical isolates.</description>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Individual Inhibitory Quotient (IQ)</title>
          <description>Individual IQ was defined at Cmin at Week 2 divided by the protein binding adjusted EC90 (ie, the drug concentration observed to inhibit virion production by 90% in a cell-based assay) values for Atazanavir that were derived from individual participant clinical isolates.</description>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>Units on a Scale</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.47" lower_limit="12.0" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atazanavir Terminal Elimination Half Life</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Atazanavir Terminal Elimination Half Life</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Raltegravir Terminal Elimination Half Life</title>
        <time_frame>At Week 2 from Baseline</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Terminal Elimination Half Life</title>
          <population>All randomized participants who received at least 1 dose of study medication and who were evaluable.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Laboratory Test Results With Worst Toxicity of Grades 1 to 4 Among All Treated Participants</title>
        <description>ULN=upper limit of normal. Hematocrit(%) Grade (Gr) 1: ≥28.5-&lt;31; Gr 2: ≥24-&lt;28.5; Gr 3: ≥19.5-&lt;24; Gr 4: &lt;19.5. Hemoglobin (g/dL) Gr 1: 9.5-11; Gr 2: 8-9.4; Gr 3: 6.5-7.9; Gr 4: &lt;6.5. Platelets (/mm^3) Gr 1: 75,000-99,000; Gr 2: 50,000-74,999; Gr 3: 20,000-49,999; Gr 4: &lt;20,000. White Blood Cells (/mm^3) Gr 1: &gt;2500-4000; Gr 2: &gt;1000-&lt;2500; Gr 3: &gt;800-&lt;1000; Gr 4: &lt;800. . Prothrombin time (seconds) Gr 1: 1.01-1.25*ULN; Gr 2: 1.26-1.5*ULN; Gr 3: 1.51-3*ULN; Gr 4: &gt;3*ULN.</description>
        <time_frame>While on treatment from Baseline through Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Laboratory Test Results With Worst Toxicity of Grades 1 to 4 Among All Treated Participants</title>
          <description>ULN=upper limit of normal. Hematocrit(%) Grade (Gr) 1: ≥28.5-&lt;31; Gr 2: ≥24-&lt;28.5; Gr 3: ≥19.5-&lt;24; Gr 4: &lt;19.5. Hemoglobin (g/dL) Gr 1: 9.5-11; Gr 2: 8-9.4; Gr 3: 6.5-7.9; Gr 4: &lt;6.5. Platelets (/mm^3) Gr 1: 75,000-99,000; Gr 2: 50,000-74,999; Gr 3: 20,000-49,999; Gr 4: &lt;20,000. White Blood Cells (/mm^3) Gr 1: &gt;2500-4000; Gr 2: &gt;1000-&lt;2500; Gr 3: &gt;800-&lt;1000; Gr 4: &lt;800. . Prothrombin time (seconds) Gr 1: 1.01-1.25*ULN; Gr 2: 1.26-1.5*ULN; Gr 3: 1.51-3*ULN; Gr 4: &gt;3*ULN.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4</title>
        <description>Blood urea nitrogen Gr 1:1.25-2.5*ULN;Gr 2:2.6-5.0*ULN; Gr 3:5.1–10*ULN; Gr 4:&gt;10*ULN. Creatinine (mg/dL) Gr 1: 1.1-1.5 *ULN; Gr 2: 1.6-3*ULN: Gr 3: 3.1-6*ULN; Gr 4: &gt;6*ULN. Hypercarbia (meq/L)Gr 1: 33-36; Gr 2:37-40; Gr 3: 41-45; Gr 4:&gt;45. Hypocarbia (meq/L)Gr 1:19-21; Gr 2: 15-18; Gr 3: 10-14; Gr 4:&lt;10. Hypercalcemia (mg/dL)Gr 1:10.6-11.5;Gr 2:11.6-12.5; Gr 3:12.6-13.5;Gr 4: &gt;13.5. Hypocalcemia (mg/dL)Gr 1: 8.4-7.8;Gr 2:7.7-7; Gr 3:6.9-6.1; Gr 4: &lt;6.1.Hyperchloremia(meq/L)Gr 1:113-116; Gr 2:117-120; Gr 3:121-125; Gr 4: &gt;125.Hypochloremia(meq/L)Gr 1: 90-93; Gr 2: 85-89; Gr 3:80-84; Gr 4:&lt;80.</description>
        <time_frame>While on treatment from Baseline through Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4</title>
          <description>Blood urea nitrogen Gr 1:1.25-2.5*ULN;Gr 2:2.6-5.0*ULN; Gr 3:5.1–10*ULN; Gr 4:&gt;10*ULN. Creatinine (mg/dL) Gr 1: 1.1-1.5 *ULN; Gr 2: 1.6-3*ULN: Gr 3: 3.1-6*ULN; Gr 4: &gt;6*ULN. Hypercarbia (meq/L)Gr 1: 33-36; Gr 2:37-40; Gr 3: 41-45; Gr 4:&gt;45. Hypocarbia (meq/L)Gr 1:19-21; Gr 2: 15-18; Gr 3: 10-14; Gr 4:&lt;10. Hypercalcemia (mg/dL)Gr 1:10.6-11.5;Gr 2:11.6-12.5; Gr 3:12.6-13.5;Gr 4: &gt;13.5. Hypocalcemia (mg/dL)Gr 1: 8.4-7.8;Gr 2:7.7-7; Gr 3:6.9-6.1; Gr 4: &lt;6.1.Hyperchloremia(meq/L)Gr 1:113-116; Gr 2:117-120; Gr 3:121-125; Gr 4: &gt;125.Hypochloremia(meq/L)Gr 1: 90-93; Gr 2: 85-89; Gr 3:80-84; Gr 4:&lt;80.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood urea nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercarbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocarbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperchloremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypochloremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperclycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4 (Continued)</title>
        <description>Hyperkalemia(meq/L) Gr 1: 5.6-6; Gr 2: 6.1-6.5; Gr 3: 6.6-7; Gr4: &gt;7. Hypokalemia(meq/L) Gr 1: 3-3.4; Gr 2: 2.5-2.9; Gr 3: 2-2.4; Gr 4:&lt;2. Hypernatremia (meq/L) Gr 1: 148-150; Gr 2: 151-157; Gr 3: 148-165; Gr 4: &gt;165. Hyponatremia (meq/L) Gr 1: 130-132; Gr 2: 123-129; Gr 3: 116-122; Gr 4: &gt;115.Hyperglycemia(mg/dL)Gr 1: 116-160; Gr 2: 161-250; Gr 3: 251-500; Gr 4: &gt;500. Hypoglycemia(mg/dL)Gr 1: 55-64; Gr 2: 40-54; Gr 3:30-39;Gr 4:&lt;30.Creatine kinase (IU/L) Gr 1: &gt;ULN-1.5*ULN; Gr 2: 1.5-3*ULN; Gr 3: &gt;3-6*ULN; Gr 4: &gt;6.0*ULN. Albumin (g/dL) Gr 1: &lt;LLN-30; Gr 2: &lt;30-20; Gr 3&amp;4: &lt;20.</description>
        <time_frame>While on treatment from Baseline through Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Chemistry Laboratory Test Results With Worst Toxicity of Grades 1 to 4 (Continued)</title>
          <description>Hyperkalemia(meq/L) Gr 1: 5.6-6; Gr 2: 6.1-6.5; Gr 3: 6.6-7; Gr4: &gt;7. Hypokalemia(meq/L) Gr 1: 3-3.4; Gr 2: 2.5-2.9; Gr 3: 2-2.4; Gr 4:&lt;2. Hypernatremia (meq/L) Gr 1: 148-150; Gr 2: 151-157; Gr 3: 148-165; Gr 4: &gt;165. Hyponatremia (meq/L) Gr 1: 130-132; Gr 2: 123-129; Gr 3: 116-122; Gr 4: &gt;115.Hyperglycemia(mg/dL)Gr 1: 116-160; Gr 2: 161-250; Gr 3: 251-500; Gr 4: &gt;500. Hypoglycemia(mg/dL)Gr 1: 55-64; Gr 2: 40-54; Gr 3:30-39;Gr 4:&lt;30.Creatine kinase (IU/L) Gr 1: &gt;ULN-1.5*ULN; Gr 2: 1.5-3*ULN; Gr 3: &gt;3-6*ULN; Gr 4: &gt;6.0*ULN. Albumin (g/dL) Gr 1: &lt;LLN-30; Gr 2: &lt;30-20; Gr 3&amp;4: &lt;20.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperclycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Enzyme and Urine Laboratory Test Results With Worst Toxicity of Grades 1 to 4</title>
        <description>AST/SGOT=Aspartate aminotransferase/serum glutamate oxaloacetate transaminase; ALT/SGPT=Alanine transaminase/serum glutamic pyruvic transaminase. Bilirubin (mg/dL)Gr 1: 1.1-1.5*ULN;Gr 2:1.6-2.5*ULN;Gr3:2.6-5*ULN;Gr4:&gt;5*ULN.AST/SGOT(U/L)Gr 1:1.25-2.5*ULN;Gr 2: 2.6-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.ALT/SGPT (U/L)Gr 1:1.25-2.5*ULN;Gr 2:1.4-2.09*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN. Lipase(U/L)Gr 1:1.1-1.39*ULN;Gr 2:&gt;1.5-2*ULN;Gr 3:2.5-5;Gr 4:5*ULN.Proteinuria(g/24 hr loss)Gr 1:1+or &lt;1;Gr 2:2-3+or&gt;1-2; Gr 3:4+or&gt;2-3.5;Gr4:&gt;3.5.Creatine kinase(IU/L)Gr1:2-3*ULN;Gr 2:3.1-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.</description>
        <time_frame>While on treatment from Baseline through Week 96</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir + Raltegravir</title>
            <description>Atazanavir, 300 mg twice daily, plus Raltegravir, 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
            <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/emtricitabine, 300 mg/200 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Enzyme and Urine Laboratory Test Results With Worst Toxicity of Grades 1 to 4</title>
          <description>AST/SGOT=Aspartate aminotransferase/serum glutamate oxaloacetate transaminase; ALT/SGPT=Alanine transaminase/serum glutamic pyruvic transaminase. Bilirubin (mg/dL)Gr 1: 1.1-1.5*ULN;Gr 2:1.6-2.5*ULN;Gr3:2.6-5*ULN;Gr4:&gt;5*ULN.AST/SGOT(U/L)Gr 1:1.25-2.5*ULN;Gr 2: 2.6-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.ALT/SGPT (U/L)Gr 1:1.25-2.5*ULN;Gr 2:1.4-2.09*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN. Lipase(U/L)Gr 1:1.1-1.39*ULN;Gr 2:&gt;1.5-2*ULN;Gr 3:2.5-5;Gr 4:5*ULN.Proteinuria(g/24 hr loss)Gr 1:1+or &lt;1;Gr 2:2-3+or&gt;1-2; Gr 3:4+or&gt;2-3.5;Gr4:&gt;3.5.Creatine kinase(IU/L)Gr1:2-3*ULN;Gr 2:3.1-5*ULN;Gr 3:5.1-10*ULN;Gr4:&gt;10*ULN.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/SGOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/ SGPT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteinurea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While on treatment from Baseline through Week 96</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atazanavir + Ritonavir + Tenofovir/Emtricitabine</title>
          <description>Atazanavir, 300 mg once daily, plus Ritonavir, 100 mg once daily, plus fixed-dose Tenofovir/Emtricitabine, 300 mg/200 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Atazanavir + Raltegravir</title>
          <description>Atazanavir 300 mg twice daily plus Raltegravir 400 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MALARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BURNS FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>KAPOSI'S SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>TESTIS CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR ICTERUS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>ACARODERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BILIRUBIN CONJUGATED INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

